Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly
become an established factor in daily (hemato)-oncology practice. Although the oral route of …

Rationale Tyrosine kinase inhibitors are increasingly used in the treatment of cancer. Drug
interactions involving tyrosine kinase inhibitors are commonly encountered in clinical …

The extensive use of tyrosine kinase inhibitors (TKI's) in hematology and oncology has
shown that these drugs have a significant potential for drug‐drug interactions. Since these …

Drug− drug interactions (DDIs) occur when a patient's response to the drug is modified by
administration or co‐exposure to another drug. The main cytochrome P 450 (CYP) enzyme …

In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and
haemato-oncology. Because this new class of drugs is extensively used, serious drug–drug …

During the past two decades, small-molecule kinase inhibitors have proven to be valuable in
the treatment of solid and haematological tumours. However, because of their oral …

Small molecular tyrosine kinase inhibitors (smTKIs) are in the centre of the very quickly
expanding area of personalized chemotherapy and oral applicability thereof. The number of …

The United States Food and Drug Administration (FDA) has approved 19 oral kinase
inhibitors (KIs) for the treatment of malignancies in hematology/oncology as of May 2013 …

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

A number of molecularly targeted anticancer drugs that efficiently inhibit receptor tyrosine
kinases, socalled receptor tyrosine kinase inhibitors (TKIs), have been developed. Although …